R1	Has_value Arg1:T2 Arg2:T3	
R2	Has_temporal Arg1:T2 Arg2:T4	
R3	AND Arg1:T1 Arg2:T2	
R4	multi Arg1:T9 Arg2:T10	
R5	Has_index Arg1:T7 Arg2:T9	
R6	Has_value Arg1:T5 Arg2:T6	
R7	Has_temporal Arg1:T5 Arg2:T7	
R8	Has_index Arg1:T12 Arg2:T13	
R9	AND Arg1:T13 Arg2:T14	
R10	Has_negation Arg1:T16 Arg2:T17	
R11	Has_value Arg1:T8 Arg2:T11	
R12	Has_index Arg1:T18 Arg2:T19	
R13	Has_temporal Arg1:T8 Arg2:T18	
R14	Has_temporal Arg1:T8 Arg2:T12	
R15	Has_qualifier Arg1:T20 Arg2:T21	
T1	Condition 0 19	Chronic hepatitis B
T2	Measurement 21 26	HBsAg
T3	Value 27 35	positive
T4	Temporal 36 46	> 6 months
T5	Measurement 49 54	HBeAg
T6	Value 55 63	negative
T7	Temporal 64 126	within six months prior to initiation of peginterferon alfa-2a
T9	Reference_point 91 126	initiation of peginterferon alfa-2a
T10	Drug 105 126	peginterferon alfa-2a
T8	Measurement 128 135	HBV DNA
T11	Value 136 147	< 200 IU/ml
T12	Temporal 209 270	within one month prior to initiation of peginterferon alfa-2a
T13	Reference_point 235 270	initiation of peginterferon alfa-2a
T14	Drug 249 270	peginterferon alfa-2a
T15	Drug 155 177	nucleos(t)ide analogue
T16	Drug 186 197	Telbivudine
T17	Negation 179 185	except
T18	Temporal 148 208	during nucleos(t)ide analogue (except Telbivudine) treatment
T19	Reference_point 155 208	nucleos(t)ide analogue (except Telbivudine) treatment
T20	Condition 284 297	liver disease
T21	Qualifier 272 283	Compensated
T22	Person 299 302	Age
T23	Value 303 313	> 18 years
T24	Informed_consent 315 339	Written informed consent
